Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cbio A/S is currently managing a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio features 2 pending office actions, indicating a moderate level of activity. This suggests that the company is pursuing multiple innovations within the biotech sector and is actively engaged in the prosecution process for at least two separate applications at the patent office.
The prosecution is distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that each pending action is being reviewed by a different examiner in a different administrative group. This variety suggests that the company's biotechnology products span different technical classifications, requiring a prosecution strategy that can adapt to the different perspectives and requirements of 2 distinct examiners and 2 distinct art units.
BUTTICE, AUDREY L is the busiest examiner, with 1 busiest examiner pending office action. With a total of 2 pending office actions, the workload is split evenly, meaning no single examiner has a dominant influence over the portfolio's current outcomes. Practitioners must be prepared to address the specific feedback from each examiner to successfully move the 2 pending office actions toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| ABBOTT, KODYE LEE | 1 | 53.1% | +71.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756814 | IMPROVED PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE | ABBOTT, KODYE LEE | 147d overdue |
| 18569874 | MULTISTEP PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE | BUTTICE, AUDREY L | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569874 | MULTISTEP PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE | BUTTICE, AUDREY L | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Dec 13, 2023 |
| 17756814 | IMPROVED PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE | ABBOTT, KODYE LEE | 1634 | §103 | Final Rejection | 147d overdue | Pending | Jun 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial